Author

C. Andrew Stewart

Institution: Cartesian Therapeutics, Inc. (United States)

Observed institution: Cartesian Therapeutics, Inc. (United States)

ORCID: 0000-0001-7936-447X

Observed ORCID: 0000-0001-7936-447X

OpenAlex ID: A5128219050

BCMA-directed mRNA CAR T cell therapy for myasthenia gravis: a randomized, double-blind, placebo-controlled phase 2b trial

2026 · Tuan Vu, Hacer Durmus, et al. · Nature Medicine · 38

BCMA-directed mRNA CAR-T cell therapy for myasthenia gravis: exploratory biomarker analysis of a placebo-controlled phase 2b trial

2026 · Renee R. Fedak, Rachel N. Ruggerie, et al. · Nature Medicine · 26

Twelve-Month Follow-Up of Patients With Generalized Myasthenia Gravis Receiving BCMA-Directed mRNA Cell Therapy

2024 · Nizar Chahin, Gregory Sahagian, et al. · medRxiv · 15

Works count: 3

Citation count: 79

H-index: 3

I10-index: 3